(Q45052983)

English

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

scientific article published on 23 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models (English)

1 reference

Europe PubMed Central

9 December 2017

Clostridium difficile

0 references

author name string

Jing-Hui Tian

1

1 reference

Europe PubMed Central

9 December 2017

Steven R Fuhrmann

2

1 reference

Europe PubMed Central

9 December 2017

Stefanie Kluepfel-Stahl

3

1 reference

Europe PubMed Central

9 December 2017

Robert J Carman

4

1 reference

Europe PubMed Central

9 December 2017

Larry Ellingsworth

5

1 reference

Europe PubMed Central

9 December 2017

David C Flyer

6

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

23 April 2012

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

30

1 reference

Europe PubMed Central

9 December 2017

28

1 reference

Europe PubMed Central

9 December 2017

4249-4258

1 reference

Europe PubMed Central

9 December 2017

Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Epidemiology of nosocomial clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Clostridium difficile toxins: mechanism of action and role in disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Comparative sequence analysis of the Clostridium difficile toxins A and B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Structural characterization of the cell wall binding domains of Clostridium difficile toxins A and B; evidence that Ca2+ plays a role in toxin A cell surface association.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Treatment with monoclonal antibodies against Clostridium difficile toxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Toxin B is essential for virulence of Clostridium difficile

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Both, toxin A and toxin B, are important in Clostridium difficile infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Molecular characterization of the Clostridium difficile toxin A gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.04.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.04.045

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45052983&oldid=2063989421"